POS0976 ANALYSIS OF BIOLOGIC THERAPY RETENTION RATE IN PSORIATIC ARTHRITIS PATIENTS WITH AND WITHOUTV AXIAL INVOLVEMENT. DATA FROM CLINICAL PRACTICE

Background: Limited data are available on retention rates of biologic therapy in psoriatic arthritis (PsA) patients (pts) with axial involvement. It has been shown that the subset pts prevalent involvement (AS versus PsA and AxSpA PsA) a longer duration anti-TNF-?-therapy was observed as compared to peripheral [1]. Objectives: To compare without routine clinical practice. Methods: 731 according CASPAR criteria were included study. Data collected from 43 rheumatology clinics over various regions Russian Federation. Among pts, 243 (33.0%) (M/F 132/111) given therapy. Pts’ age 45.9±12.8 years (yrs), disease 8.6±6.5 yrs. Pts underwent standard examination activity split into two groups (gr.), (axPsA): axPsA(+) axPsA(-). gr. had inflammatory back pain by ASAS and/or radiographic sacroiliitis (SI) (unilateral grade?3 or bilateral grade?2) active MRI SI typical axPsA changes cervical lumbar spine (marginal/paramarginal syndesmophytes, ankylosis facet joints). axPsA(-) only arthritis. The 143 (58.8%) 100 (41.2%) pts. 163 (67.1%) treated TNF inhibitors (TNF-i), 80 (32.9%) interleukin (IL-i): 55 Ustekinumab, 25 Secukinumab. During TNF-i treatment courses Infliximab 34 Adalimumab 53 Etanercept 36 Golimumab 27 Certolizumab Pegol 8 observation period lasted 12 months. Treatment analyzed using Kaplan-Meier curves log-rank test. Results: Analysis revealed statistically significant differences between grs. After months observation, 72.9% continued receiving therapy, while 53.1% (?=0.0027) received it. same kind anti-TNF found gr.: 82.2% 62.3% respectively (?=0.011) after However no IL-i therapy: 55.5% 37% (?=0.086) IL-i. Conclusion: In practice, be worse prescribed twice often than However, considering need personalized case use is preferable because their don’t depend References: [1]M. Fabbroni et al. Mediators Inflammation, 2014. Retention Differences (?=0.00265, log rank test). Disclosure Interests: None declared.